A gastric peptide studied for systemic tissue repair.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Preclinical research describes accelerated tendon, ligament and gut-lining repair through angiogenesis and growth-factor upregulation.
Animal models show accelerated healing of transected tendons and ligaments, with increased fibroblast migration and collagen organization.
Originally studied for GI protection; models demonstrate mucosal healing and protection against NSAID-induced damage.
Upregulation of VEGF signaling improves blood supply to healing tissue — the rate-limiting factor in tendon recovery.
Reduced pro-inflammatory cytokine expression in injury models without the immunosuppression of corticosteroids.
Often stacked alongside GLP-1 protocols where training volume rises and recovery capacity is compressed.
Reported side effects in the literature are minimal, though long-term human safety data remains limited.
BPC-157 appears to act as a systemic cytoprotective agent rather than binding a single receptor. Research points to modulation of the nitric oxide system, growth-factor receptor upregulation, and stabilization of the gut-brain axis.
Increased expression of VEGFR2 and FAK-paxillin signaling in fibroblasts.
New capillary formation improves oxygen and nutrient delivery to injured tissue.
Fibroblast outgrowth and improved tensile strength in healing tendon models.
Interaction with the NO system supports vascular tone and mucosal integrity.
The great majority of BPC-157 research is preclinical — rodent and in-vitro models. Results are consistent and mechanistically coherent, but large randomized human trials have not been completed. We prescribe it as an off-label adjunct with that transparency, not as a proven therapy.
BPC-157 is widely sold as an unregulated 'research chemical.' Ours is compounded by a licensed U.S. pharmacy under a physician prescription with certificates of analysis — purity and dosing accuracy are not optional in peptide therapy.
Typical protocols run four to eight weeks with a washout. It is commonly paired with TB-500 for soft-tissue injury or used alongside GLP-1 therapy during high training volume.
BPC-157 is prohibited under WADA's S0 category. Competitive athletes subject to testing should not use it.
Accelerated tendon-to-bone healing and increased fibroblast outgrowth in rat Achilles models.
Journal of Applied Physiology
Review of cytoprotective effects across GI, tendon, muscle and nerve injury models.
Current Pharmaceutical Design
Systematic review concluding consistent preclinical benefit with a call for human trials.
Cell and Tissue Research
Illustrative only. Your physician sets and adjusts your schedule based on tolerance, labs and rate of progress — escalation is never automatic.
| Phase | Dose | Clinical note |
|---|---|---|
| Weeks 1–2 | 250 mcg daily | Assess tolerance. |
| Weeks 3–6 | 250–500 mcg daily | Injected near the target area where practical. |
| Weeks 7–8 | 250 mcg daily | Taper toward washout. |
| Washout | — | 4 weeks off before repeating a cycle. |
Most side effects are dose-dependent and resolve with slower titration. Your care team is reachable by message, and holding a dose is always an option.
| Therapy | Mechanism | Avg. weight change | Frequency |
|---|---|---|---|
| BPC-157 | Cytoprotective / angiogenic | — | Daily |
| TB-500 | Actin-binding, cell migration | — | 2x weekly |
| CJC-1295 / Ipamorelin | GH secretagogue | — | Nightly |
No. It is prescribed off-label and compounded by a licensed U.S. pharmacy. Human clinical trial data is limited, and your physician will review that with you before prescribing.
Subcutaneously, commonly near the area being treated. Your care team provides site guidance during onboarding.
Yes — it is one of our most common stacks, used to support recovery and gut comfort during a caloric deficit.
Most protocols run four to eight weeks followed by a four-week washout, then reassessment with your physician.
The clinical gold standard for appetite regulation.
View protocolDual incretin action for the deepest documented weight reduction.
View protocolA synthetic fragment of Thymosin Beta-4 studied for soft-tissue recovery.
View protocolA paired secretagogue protocol that supports your own growth hormone rhythm.
View protocolA mitochondrial cofactor protocol for energy, focus and cellular repair.
View protocolThe same GLP-1 signal, taken as a daily oral dose instead of a weekly injection.
View protocolA mitochondrial-derived peptide studied for metabolic flexibility and exercise-like signaling.
View protocolAn on-demand therapy that works on desire in the brain, not blood flow in the body.
View protocolIntranasal peptides studied for focus, stress resilience and neurotrophic support.
View protocolThe original growth hormone-releasing peptide — simpler and gentler than newer secretagogue combinations.
View protocolA two-minute intake, reviewed by a licensed physician. No obligation, no membership fee.